Home About Us Products Clinical Trials News Investors Contact Pioneering stem cell therapeutics We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. Learn More About ReNeuron Latest News View all Interim Results for the six months ended 30 September 2021 New CTX-iPSC platform data shows potential in Peripheral Nerve Repair Notice of Results – Investor presentation Collaboration agreement with UCL First subject treated at Oxford Eye Hospital in Phase 2a RP trial Share Price More details 93.5p -1.50p at 02-12-2021 10:52:00 15 minute delayed share price from London Stock Exchange provided by Euroland. Our Products & Technologies Read more Clinical Trials Read more Investor Centre Read more Subscribe here for our Press Releases: The information collected will be used to send you the information you have requested and to provide information that may be useful to you. ReNeuron may share non-personal aggregate statistics (group) data about ReNeuron’s website visitors with partners or other parties. However, ReNeuron will not sell or share any information about individual users. Please ensure you have read the full contents of our Privacy Notice before continuing. If you agree to your information being used in this way, please tick the box: I agree Click here © ReNeuron Group plc 2021 All rights reserved Website design by Carr Kamasa Design Privacy Notice Disclaimer